Reimbursement, Patient Switches Create Entry Point For Vanda’s Fanapt

Launching a "me too" product with a serious safety risk in a crowded field is not an easy task. But with the right profile and the right expectations, Vanda may have found the perfect entry point for its atypical antipsychotic Fanapt (iloperidone)

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet